Aucuba Sciences

Aucuba Sciences is a private, preclinical-stage biotech focused on developing transformative therapies for neurodegenerative diseases by targeting the fundamental biology of aging. The company's core technology platform is built on research into cellular senescence and proteostasis, aiming to develop disease-modifying treatments rather than symptomatic relief. With a strong scientific foundation and experienced leadership team, Aucuba is working to advance its lead candidate toward clinical development while exploring broader applications of its aging-focused platform. The company represents a novel approach in the competitive neurodegeneration space, seeking to alter disease progression rather than merely manage symptoms.

Aging biology platform targeting cellular senescence, proteostasis, and mitochondrial function to develop disease-modifying therapies for neurodegenerative conditions.

Aucuba competes against large pharma with amyloid-targeting antibodies (Biogen/Eisai, Eli Lilly) and biotech companies pursuing alternative mechanisms like neuroinflammation (Alector) or senescence (Unity). Its differentiation lies in its specific focus on CNS aging mechanisms, but it must demonstrate superior efficacy or safety to overcome entrenched competitors.